<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> is associated with increased <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and is a well-recognized factor for the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Unfortunately, most <z:mp ids='MP_0002055'>diabetes</z:mp> therapies are associated with further <z:mp ids='MP_0005456'>weight gain</z:mp>, a most unwelcome characteristic, given the association of <z:mp ids='MP_0005456'>weight gain</z:mp> with deteriorating metabolic control, worsening cardiovascular profiles and decreased adherence to treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Therapies that effectively control glycaemia without <z:mp ids='MP_0005456'>weight gain</z:mp> or with concomitant <z:hpo ids='HP_0001824'>weight loss</z:hpo> are needed </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this article was to review the existing preclinical and clinical evidences, showing that the family of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1)-based therapies fulfils these criteria by harnessing the beneficial properties of GLP-1, a naturally occurring incretin hormone with a strong blood <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering action and the ability to induce <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
</text></document>